Overcoming platinum resistance in ovarian cancer treatment: from clinical practice to emerging chemical therapies-Reference-Cited by-同舟云学术

Overcoming platinum resistance in ovarian cancer treatment: from clinical practice to emerging chemical therapies

Published:2017-08-18 Issue:14 Volume:18 Page:1443-1455
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Tomao Federica¹,Marchetti Claudia¹,Romito Alessia¹,Di Pinto Anna¹,Di Donato Violante¹,Capri Oriana¹,Palaia Innocenza¹,Monti Marco¹,Muzii Ludovico¹,Benedetti Panici Pierluigi¹

Affiliation:

1. Department of Gynaecology and Obstetrics, “Sapienza” University of Rome, Rome, Italy

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2017.1328055

Reference82 articles.

1. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

2. Ovarian cancer

3. 2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer: Report From the Fourth Ovarian Cancer Consensus Conference

4. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of mirvetuximab soravtansine in recurrent ovarian cancer with FRa positive expression: A systematic review and meta-analysis;Critical Reviews in Oncology/Hematology;2024-02

2. Selinexor in Combination with Decitabine Attenuates Ovarian Cancer in Mice;Cancers;2023-09-13

3. Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer;Expert Review of Anticancer Therapy;2023-07-24

4. Regulatory Role of the Adipose Microenvironment on Ovarian Cancer Progression;Cancers;2022-05-01

5. Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer;Gynecologic Oncology;2022-03